Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
President at High Point Clinical Trials Center, US
Dr. Rusch is an executive level business development professional and drug development scientist specializing in early clinical development services as President at High Point Clinical Trial Center. Her specialized background allows her to provide a consultative service tailored to the needs of biotechnology and pharma clients. Dr. Rusch earned her Ph.D. in Laboratory Medicine and Bioanalytical Chemistry from the Cleveland Clinic Foundation/Cleveland State University Consortium. She has significant drug development expertise in the biotechnology industry as well as operational expertise in early clinical development contract research organizational leadership. Dr. Rusch provided preclinical, clinical pharmacology and metabolism expertise on many pre-IND drug development teams, including Merck’s Zolinza™ program, a first-in-class histone deacetyylase inhibitor (HDAC) currently approved for the treatment of cutaneous T-cell lymphoma and under study for additional indications. Dr. Rusch’s current interest is the creation of viable strategies for clients focused in achieving Proof of Concept (POC) in Phase I/IIa by use of adaptive clinical trials involving both healthy normal subjects and patient populations.